Biocon, Bristol-Myers in deal for oral insulin drug
MUMBAI (Reuters) - Biocon Ltd, India's top-listed biotechnology company, said it signed an agreement with Bristol-Myers Squibb Co under which the U.S. drugmaker will have the option to get the worldwide license to its oral insulin drug program.
Bristol Myers can choose to assume full responsibility for the development of the drug IN-105, if its mid-stage trial is successful.
Biocon, which has been looking to partner the drug for nearly two years, said it would receive a license fee as well as milestone payments and royalties based on commercial sales of the drug outside India. It will retain the rights to IN-105 in India.
Financial terms of the deal were not available.
Currently, there are no insulin tablets available and patients with diabetes who need insulin -- a naturally occurring protein that controls blood sugar -- must inject it.
Earlier this year, Pfizer scrapped a deal to sell injectable insulin products made by Biocon.
Biocon shares, which rose more than 4 percent in the previous session, were down 0.4 percent on Friday, while the broader market was up 0.3 percent.
(Reporting by Aradhana Aravindan; Editing by G.Ram Mohan)
- Britain's Vodafone has agreed to buy Spanish cable operator Ono for 7.2 billion euros ($10.03 billion) in a deal that is set to be announced on Monday, a person familiar with the matter told Reuters.
LONDON - Lloyds Bank said it will grow its lending to small-and-medium enterprises (SMEs) by a further 1 billion pounds this year, seeing stronger growth prospects for smaller businesses as Britain's economic recovery takes hold.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.